Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The FDA pushed back its decision date on Cytokinetics heart drug, while AstraZeneca got Phase 3 trial results that could help ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

Siren Biotechnology is trying to raise $5 million via the type of crowdfunding round that’s rarely used by young drugmakers.

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on Thursday.

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...